Furthermore, preclinical models demonstrate that early inhibition of LAG3 significantly enhances prognosis in GBM-bearing mice and is highly effective in tumor eradication when combined with anti-PD-1/PD-L1 therapy (24). Here, PDCD1 is linked to neoplasm.